HC Wainwright Has Negative Estimate for IPA FY2028 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Analysts at HC Wainwright cut their FY2028 EPS estimates for ImmunoPrecise Antibodies in a research report issued on Wednesday, December 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.13 per share for the year, down from their previous forecast of $0.14. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ FY2029 earnings at $0.24 EPS.

ImmunoPrecise Antibodies Stock Performance

NASDAQ:IPA opened at $0.40 on Thursday. ImmunoPrecise Antibodies has a 1 year low of $0.32 and a 1 year high of $2.60. The stock’s fifty day moving average price is $0.47 and its two-hundred day moving average price is $0.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.99 and a quick ratio of 0.82. The company has a market cap of $11.63 million, a P/E ratio of -0.52 and a beta of 0.06.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its quarterly earnings results on Monday, September 16th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 70.69%. The business had revenue of $3.85 million for the quarter, compared to analysts’ expectations of $4.96 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC raised its position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,910 shares of the company’s stock after purchasing an additional 26,310 shares during the period. Renaissance Technologies LLC owned 0.24% of ImmunoPrecise Antibodies worth $65,000 at the end of the most recent reporting period. 6.70% of the stock is owned by institutional investors and hedge funds.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.